Press release
Non-Small Cell Lung Cancer (Nsclc) Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033
Non-Small Cell Lung Cancer (Nsclc) Market Overview
According to The Business Research Company's, the gastrointestinal stromal tumor market size has grown strongly in recent years. It will grow from $1.18 billion in 2023 to $1.28 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased awareness and early diagnosis, emergence of targeted therapies, enhanced surgical techniques, development of personalized medicine, improvements in supportive care.
The gastrointestinal stromal tumor market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to continued research and drug development, rise in patient-centric healthcare, integration of precision medicine in clinical practice, increasing access to targeted therapies, expanding genomic profiling capabilities. Major trends in the forecast period include growing collaboration in research and development, advancements in diagnostic technologies, collaborative research and clinical trials, increased focus on early detection and diagnosis, exploration of combination therapies.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report
Market Drivers and Trends:
The increasing rate of tobacco consumption is expected to propel the growth of the non-small cell lung cancer (NSCLC) market going forward. Tobacco consumption refers to the use of tobacco products by individuals, typically in the form of smoking, chewing, or snuffing, which introduces nicotine and other chemicals into the body. Tobacco smoke contains several carcinogens that can damage the DNA (deoxyribonucleic acid) in lung cells, leading to mutations and the uncontrolled growth of cancerous cells, including non-small-cell lung cancer (NSCLC). For instance, in July 2022, according to Statistics Canada, a Canada-based government agency, cigarette production increased by 5.8% compared to June 2021. The total number of cigarettes sold rose 1.3% from May 2022, reaching 1.4 billion in June 2022. Therefore, the increasing rate of tobacco consumption is driving the growth of the non-small cell lung cancer (NSCLC) market.
Major Companies operating in the non-small cell lung cancer (NSCLC) market are focused on developing multiple treatment options, such as monotherapy treatments, to gain a competitive edge. Monotherapy treatment is the use of a single drug or therapy to treat a medical disorder or condition, and it involves utilizing a single method or treatment approach rather than a combination of multiple interventions. For instance, in June 2022, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the European Commission (EC), a Belgium-based governing body, for Tabrecta (capmatinib) for the treatment of adult patients with advanced non-small cell lung cancer with METex14 skipping. It offers a novel targeted therapeutic option for patients in Europe who have received prior treatment and have advanced non-small cell lung cancer (NSCLC) that has mutations that cause MET exon 14 (METex14) skipping. It is the most popular targeted treatment for advanced NSCLC and has modifications that cause METex14 skipping.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp
Major Key Players of the Market:
Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC) Market 2024 Key Insights:
• The non-small cell lung cancer (nsclc) market is expected to grow to $29.95 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%.
• Rising Tobacco Consumption Fuels Growth In The Non-Small Cell Lung Cancer (NSCLC) Market
• Rising Focus Of Companies To Embrace Advance Treatments To Gain Competitive Advantage
• North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13232&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Small Cell Lung Cancer (Nsclc) Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033 here
News-ID: 3667547 • Views: …
More Releases from The Business research company
Top Players and Competitive Dynamics in the Rocket Capsule Recovery Market
Exploring the Future of the Rocket Capsule Recovery Market
The rocket capsule recovery market is set to experience substantial expansion over the coming years. Driven by technological advancements and increasing commercial space activities, this industry is poised for significant growth by 2030. Let's delve into the market size projections, key players, emerging trends, and segment details that shape this evolving sector.
Projected Market Size and Growth Trajectory of the Rocket Capsule…
Analysis of Segmentation, Market Dynamics, and Competitive Landscape in the Robo …
The robotic arm technology designed for space applications is rapidly advancing, driven by increasing demand for sophisticated operations beyond Earth's atmosphere. As space missions become more complex, the need for precise, autonomous robotic arms is growing, opening new avenues for satellite servicing, construction, and maintenance in orbit. Here's an in-depth look at the market size, key players, emerging trends, and segmentations shaping the future of robotic arms for space.
Robotic Arm…
Leading Companies Advancing Innovation and Growth in the Reusable Rocket Market
The reusable rocket market is gaining remarkable momentum as innovations and growing commercial interest drive its expansion. With increasing adoption by satellite operators and advances in technology, this sector is set to experience substantial growth by 2030. Let's explore the current market size, key players, emerging trends, and how the industry is shaping up for the future.
Projected Market Growth for Reusable Rockets by 2030
The reusable rocket market is anticipated…
Analysis of Segments and Major Growth Areas in the Rapid Prototyping Market for …
The aerospace and defense sectors are increasingly relying on rapid prototyping technologies to accelerate innovation and improve efficiency. This market is gaining momentum, driven by advancements in manufacturing methods and growing demands for high-precision components. Let's explore the current market valuation, key players, emerging trends, and major segments shaping the rapid prototyping industry within aerospace and defense.
Projected Market Growth and Size in Rapid Prototyping for Aerospace and Defense
The rapid…
More Releases for NSCLC
NSCLC Treatment Market to Reach USD 55.30B by 2035
Non-Small Cell Lung Cancer Treatment Market: Growth Drivers, Innovation, and the Future of Lung Cancer Care
The Non-Small Cell Lung Cancer (NSCLC) Treatment Market is undergoing a profound transformation as advances in diagnostics, targeted therapies, and immuno-oncology redefine how lung cancer is managed globally. NSCLC accounts for nearly 85% of all lung cancer cases, making it the most prevalent and commercially significant segment of the lung cancer therapeutics market.
Historically, NSCLC was…
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
